Search

… injections in the eye and has been granted orphan drug designation in the United States and the European Union …

… two dosing cohorts and is intended to inform next steps in development. We also plan to provide an update from the … Rare Pediatric Disease designation from the Food and Drug Administration (FDA). Granted access to the PRIority … data from the study are expected in 2021. Received Orphan Drug designation and Fast Track designation from the FDA. …

… of efficacy for the purpose of informing next steps in development and future trial strategy,” said David Rodman, M.D., Executive Vice President of Research and Development of ProQR. “We are pleased with the current safety … injections in the eye and has been granted orphan drug designation in the US and the European Union and …

… injections in the eye and has been granted orphan drug designation in the United States and the European Union …

… ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer LEIDEN, the Netherlands, March … Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational …

… fibrosis (CF) patients in mid-2017. Investigational new drug (IND) application for QR-110, ProQR’s lead program in … 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … Strategy Officer. Dr. Rodman has had a long career in drug development including leadership roles in translational …

… held on April 8 - 10 in Monte Carlo, Monaco. World Orphan Drug Congress USA On Thursday, April 26, 2018 at 5:20 pm ET, … companies are ramping up innovation to boost orphan drug development and patient centricity’ during the World …

… as Senior Corporate Officer, Head of Global Research and Development and Chief Scientific Officer at Santen, a global … With more than 20 years of experience in global drug development, Dr. Shams has played a significant role in …